SCHEMBL20073869

SCHEMBL20073869

CCCCCCCCCCCCCCCCCCCCCCCCCC1(CCCCCCCCCCCCCCCCCCCCCCCC)CCC2(CC1)OCCO2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19066498 0.87 SIRT2 (0.36)
SCHEMBL28008290 0.82 TSHR (0.47)
SCHEMBL12346125 0.81 KMT2A (0.35)
SCHEMBL3566912 0.80 KMT2A (0.36)
SCHEMBL2807710 0.80 TSHR (0.41)
SCHEMBL19449959 0.78 OPRM1 (0.38)
SCHEMBL15300376 0.78 SLC6A4 (0.38)
Ammonia Solution, Strong SCHEMBL27517072 0.78 TSHR (0.39)
SCHEMBL11236740 0.77
SCHEMBL21422491 0.76 SIRT2 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP disclosed
WO-2018069732-A1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LIMITED (GB) 2018-04-19 WO disclosed